Here's Why Axsome Therapeutics Rocketed 61.5% Higher in April
Shares of Axsome Therapeutics (NASDAQ: AXSM), a clinical-stage biopharmaceutical company, rocketed 61.5% in April, according to data from S&P Global Market Intelligence. In addition to recovering from a coronavirus-fueled market crash in March, pivotal data from two successful studies pushed up the stock last month.
March was a rough month for Axsome Therapeutics shareholders. In addition to pandemic-inspired panic selling, the stock took a beating after the company announced a late-stage mishap with its lead candidate, AXS-05.
Image source: Getty Images.
Source Fool.com